v3.26.1
Stockholders’ Deficit (Details Narrative) - USD ($)
3 Months Ended 6 Months Ended
Apr. 01, 2025
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Class of Stock [Line Items]          
Number of stock options exercised   0 0 0 0
Research and development expense   $ 305,944 $ 322,070 $ 611,995 $ 637,170
Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount   618,613   $ 618,613  
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition       5 months 3 days  
Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense          
Class of Stock [Line Items]          
Research and development expense   292,454 308,580 $ 585,163 610,338
Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense          
Class of Stock [Line Items]          
Research and development expense   $ 13,490 $ 13,490   $ 26,832
Consultant Options [Member]          
Class of Stock [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period 5 years        
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures 120,000        
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price $ 480,000        
Stock options exercise price per share $ 0.30        
Series D-1 Convertible Preferred Stock [Member] | Director [Member]          
Class of Stock [Line Items]          
Shares issued upon conversion   189,554      
Conversion of principal   $ 542,501      
Share price   $ 2.862   $ 2.862  
2025 Notes [Member] | Series D-1 Convertible Preferred Stock [Member]          
Class of Stock [Line Items]          
Shares issued upon conversion   203,859   375,594  
Conversion of principal   $ 540,000   $ 995,000  
Conversion of accrued interest   $ 43,434   $ 79,935